Private Banking|Professional Solutions|Investment Management|Investment Banking|About us
Van Lanschot Kempen Logo
  • Solutions
  • Sectors
  • Careers
Nov 2016
Joint Bookrunner
€ 46.4 million
Rights Issue


Transgene focuses on the development of targeted immunotherapies for the treatment of cancer and infectious diseases

  • Rights issue amounting to €46.4m.
  • Proceeds will be used to fund its clinical development plan with the launch of seven clinical trials.
  • Kempen & Co acted as Joint Bookrunner in the transaction.

Fully focused on your future

Private Banking
  • Offices
  • Entrepreneurs
  • Healthcare
  • Executives
  • Business professionals
  • Wealth management
  • Conditions
  • Private Banking - Belgium
  • Private Banking - Switzerland

Professional Solutions
Investment Management
Investment Banking

© Van Lanschot Kempen NV 2023About usSecurity and fraud awarenessPrivacy & cookiesDisclaimer